P Ruggenenti1, G Remuzzi. Show Affiliations » 1. Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.
Abstract
Entities: Disease
Mesh: See more » AdolescentAdultAge FactorsBlood TransfusionChildEndothelium, Vascular/injuriesEndothelium, Vascular/pathologyFemaleHemolytic-Uremic Syndrome/physiopathologyHumansImmunosuppressionMaleMicrocirculationMiddle AgedNeoplasms/complicationsOxidative StressPlasmaPlasma ExchangePlatelet AggregationPlatelet Aggregation Inhibitors/therapeutic usePregnancyPregnancy Complications, Hematologic/physiopathologyPregnancy Complications, Hematologic/therapyPurpura, Thrombotic Thrombocytopenic/etiologyPurpura, Thrombotic Thrombocytopenic/physiopathologyPurpura, Thrombotic Thrombocytopenic/therapySplenectomySurvival Ratevon Willebrand Factor/metabolism
Substances: See more » Platelet Aggregation Inhibitorsvon Willebrand Factor
Year: 1996 PMID: 8641387 DOI: 10.1111/j.1600-0609.1996.tb01930.x
Source DB: PubMed Journal: Eur J Haematol ISSN: 0902-4441 Impact factor: 2.997